[{"id":"c4731e51-7766-4350-abdf-25fad48c4b2c","acronym":"LEAN 2","url":"https://clinicaltrials.gov/study/NCT02110641","created_at":"2021-01-18T09:45:38.107Z","updated_at":"2024-07-02T16:35:55.183Z","phase":"","brief_title":"Lifestyle, Exercise and Nutrition Study 2 (LEAN 2)","source_id_and_acronym":"NCT02110641 - LEAN 2","lead_sponsor":"Yale University","biomarkers":" HER-2 • ER • PGR • IGF1 • IR • CRP • LEP","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR • IGF1 • IR • CRP • LEP"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2023-02-20"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"}]